Advanced Drug Delivery For Alzheimer's Disease Using Targeted Nanoparticles Across The Blood-Brain Barrier

Abstract

Recent discoveries in the field of medication delivery for Alzheimer's disease (AD) have focused on the use of customised nanoparticles as a means of breaking the blood-brain barrier (BBB) and boosting the efficacy of therapeutic interventions. This is because the BBB is a barrier that prevents blood from reaching the brain. The small size of nanoparticles, their capacity to modify their surfaces, and their biocompatibility make it possible for them to transport drugs to the brain in an accurate manner. Because of these characteristics, nanoparticles are a material that is both unique and useful. Through the implementation of this focused technique, the objective is to simultaneously increase the bioavailability of the medicine in the brain while simultaneously limiting the occurrence of systemic side effects. There are a number of different types of nanoparticles that have been investigated for their potential to deliver medications that target significant pathological aspects of Alzheimer's disease (AD), such as amyloid-beta plaques and neuroinflammation. These nanoparticles include magnetic nanoparticles, solid lipid nanoparticles, polymeric nanoparticles, and liposomes. Preclinical models of Alzheimer's disease (AD) have revealed promising findings, exhibiting improved drug delivery efficiency and therapeutic outcomes. These findings have been demonstrated by investigations. This study discusses the use of targeted nanoparticles as a sophisticated drug delivery system for the treatment of Alzheimer's disease. Additionally, the paper discusses the current developments, challenges, and potential future applications of this method.